BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38113329)

  • 1. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?
    van der Hiel B; Aalbersberg EA; van den Eertwegh AJM; de Wit-van der Veen LJ; Stokkel MPM; Lopez-Yurda M; Boellaard R; Kapiteijn EW; Hospers GAP; Aarts MJB; de Vos FYFL; Boers-Sonderen MJ; van der Veldt AAM; de Groot JWB; Haanen JBAG
    Clin Nucl Med; 2024 Feb; 49(2):138-145. PubMed ID: 38113329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
    Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
    Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.
    Schmitt RJ; Kreidler SM; Glueck DH; Amaria RN; Gonzalez R; Lewis K; Bagrosky BM; Kwak JJ; Koo PJ
    Nucl Med Commun; 2016 Feb; 37(2):122-8. PubMed ID: 26440571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.
    van der Hiel B; Haanen JBAG; Stokkel MPM; Peeper DS; Jimenez CR; Beijnen JH; van de Wiel BA; Boellaard R; van den Eertwegh AJM;
    BMC Cancer; 2017 Sep; 17(1):649. PubMed ID: 28915798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of
    Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
    Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients: Can (Early) Metabolic Imaging Predict Histopathologic Response or Recurrence?
    van der Hiel B; Blankenstein SA; Aalbersberg EA; Wondergem M; Stokkel MPM; van de Wiel BA; Klop WMC; van Akkooi ACJ; Haanen JB
    Clin Nucl Med; 2022 Jul; 47(7):583-589. PubMed ID: 35452004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
    Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
    Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim [
    Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.
    Carlino MS; Saunders CA; Haydu LE; Menzies AM; Martin Curtis C; Lebowitz PF; Kefford RF; Long GV
    Eur J Cancer; 2013 Jan; 49(2):395-402. PubMed ID: 22981500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
    Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S
    Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of
    Houard C; Pinaquy JB; Mesguich C; Henriques de Figueiredo B; Cazeau AL; Allard JB; Laharie H; Bordenave L; Fernandez P; Vendrely V
    J Nucl Med; 2017 Sep; 58(9):1414-1420. PubMed ID: 28280225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study.
    Barrington SF; Mir F; El-Galaly TC; Knapp A; Nielsen TG; Sahin D; Wenger M; Kostakoglu L; Trotman J; Meignan M
    J Nucl Med; 2022 Aug; 63(8):1149-1154. PubMed ID: 34857656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Metabolic Parameters and Textural Features in Pretreatment
    Wang G; Si Y; Liu J; Wang W; Yang J
    Acad Radiol; 2024 Mar; 31(3):1091-1101. PubMed ID: 37748956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
    Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM
    Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.
    McArthur GA; Puzanov I; Amaravadi R; Ribas A; Chapman P; Kim KB; Sosman JA; Lee RJ; Nolop K; Flaherty KT; Callahan J; Hicks RJ
    J Clin Oncol; 2012 May; 30(14):1628-34. PubMed ID: 22454415
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
    J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapy in Advanced Melanoma With Rare
    Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
    J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Baseline
    Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
    J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.